Halozyme Therapeutics (NASDAQ: HALO)
Halozyme Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Halozyme Therapeutics Company Info
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
News & Analysis
Would Halozyme Make a Good Warren Buffett Stock?
In some ways, this healthcare stock is outside his wheelhouse. But there could be attractions.
Are Biotech Stocks a Good Hedge Against Higher Inflation?
It’s worth putting a few of your eggs into this basket if you’re worried about currency devaluation.
Why Halozyme Therapeutics Is Trading 14% Higher Today
Investors liked what they saw in the company's fourth-quarter earnings release.
Can Halozyme Therapeutics Continue Its Momentum in 2020?
The biopharma's strategic moves in 2019 may set the company up for long term growth
3 Cancer Treatment Stocks to Buy in March
Find out why these oncology-focused companies stand out as great opportunities right now.
This News Explains Halozyme Therapeutics' Double-Digit Drop Today
Shares fall after an analyst lowers his price target. Here's what investors need to know.
3 Top Stocks Wall Street Is Overlooking
Just because investors are ignoring these three gems doesn't mean that you have to.
Why Halozyme Therapeutics, Inc. Deserves Its 52-Week High
Investors cheer better-than-expected earnings and a guidance boost. Could there be more upside ahead?
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.